Akerna Flash Report: 420 Cannabis Sales Reach $154.4 Million
DENVER – Akerna (Nasdaq: KERN), an enterprise software company and the developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today announced that April 20, 2022, broke all previous cannabis retail records, bringing in a total of $154.4 million in adult-use and medicinal sales.
Compared to last year’s 420, which until last week was the industry’s largest sales day to date and brought in nearly $112 million, this year’s 420 was a significant 38.1% growth over last year’s sales.
US National Retail Cannabis Sales:
When looking at the period around 420, US shoppers spent a total of $485.3 million on cannabis products. To put that into perspective, the Iowa Alcoholic Beverages Division recently reported the state’s largest year of liquor sales ever – which surpassed $400 million for the first time. This means that the US cannabis retail industry brought in more sales in just six days than Iowa did for liquor sales in a record-breaking year of their own.
“Using our historical Akerna data, we released a prediction report that the period around 420 would bring in a total of $494 million, only –1.79% variance from the actual sales of $485.3 million. This is a testament to the power of our data analytics. By leveraging data-driven insights, cannabis businesses can make strategic predictions and decisions for their businesses,” said James Ahrendt, Business Intelligence Architect at Akerna.
Akerna data has shown increases in cannabis sales market share for women shoppers over the past few years. This trend continued with this 420, with women’s market share of sales breaking the 40% mark for the first time ever.
As more markets legalize cannabis and more Americans become comfortable with the legal cannabis industry, these year-over-year increases are expected to continue. Data shows cannabis has a broad appeal to people of all demographics.
Other predicted values for the long “holiday” weekend (4/15 – 4/20)
- Category sales:
- Flower – 48.11%
- Cartridge/Pens – 31.66%
- Concentrates – 11.63%
- Infused Edibles – 6.87%
- Infused Non-Edible – 0.71%
- Non-Medicated – 1.01%
Sales by demographic:
- Men – 59.93%
- Women – 40.07%
Sales by age groups:
- Under 30 – 28.38%
- 30-40 –30.43%
- 40-50 – 19.92%
- 50-60 – 11.49%
- Over 60 – 9.78%
Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such terms or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding the ability of the MJ Platform team to help operators make decisions through analytics and reporting. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include (i) Akerna’s ability to maintain relationships with customers and suppliers and retain its management and key employees, (ii) changes in applicable laws or regulations, (iii) changes in the market place due to the coronavirus pandemic or other market factors, (iv) and other risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under “Risk Factors” therein. You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources believed to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.
(This information is primarily sourced from Akerna. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Arizona Legislature Seeks to Slash Medical Cannabis Card Prices Amid Declining Sales and Patient Numbers
PHOENIX-- In an effort to revive Arizona's struggling medical cannabis market, lawmakers are pushing forward a bill aimed at reducing the cost of medical cannabis cards. Senate Bill 1466, which received approval from the state ...
New York Regulators Pave the Way for Cannabis Farmers’ Markets Amid Supply Glut
NEW YORK-- In a bid to address the surplus of cannabis products and support local cultivators, regulators in New York have announced plans to introduce cannabis farmers' markets this summer. The move, spearheaded by the ...
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...